替格瑞洛联合阿司匹林、替格瑞洛单药或阿司匹林单药对冠状动脉旁路移植术后1年大隐静脉桥血管通畅性的影响:一项随机临床试验
该随机、多中心、开放标签试验纳入500例择期CABG患者,1:1:1分配至替格瑞洛+阿司匹林组、替格瑞洛单药组或阿司匹林单药组。1年桥血管通畅率分别为88.7%、82.8%和76.5%;替格瑞洛+阿司匹林较阿司匹林单药显著提高通畅率(差异12.2%,95%CI 5.2%-19.2%,P<.001),替格瑞洛单药与阿司匹林单药差异无统计学意义(6.3%,95%CI -1.1%-13.7%,P=.10)。
要点
- 替格瑞洛联合阿司匹林较阿司匹林单药显著提高CABG术后1年大隐静脉桥血管通畅率。
- 替格瑞洛单药与阿司匹林单药在1年桥血管通畅率上无显著差异。
- 1年随访期间共发生5例大出血事件(替格瑞洛+阿司匹林组3例,替格瑞洛单药组2例)。
核心结论
- 在择期CABG使用大隐静脉桥的患者中,替格瑞洛联合阿司匹林较阿司匹林单药显著提高术后1年桥血管通畅率。
- 替格瑞洛单药与阿司匹林单药在1年桥血管通畅率上无显著差异。
研究设计与样本
- 随机、多中心、开放标签临床试验,在中国6家三级医院开展。
- 纳入18至80岁有择期CABG指征的患者,排除需紧急血运重建、合并心脏手术、术后需双联抗血小板或维生素K拮抗剂治疗及存在严重出血风险者。
- 替格瑞洛+阿司匹林组168例,替格瑞洛单药组166例,阿司匹林单药组166例;CABG术后24小时内开始用药。
- 461例(92.2%)完成试验,随访至2017年1月。
主要发现
- CABG术后1年大隐静脉桥血管通畅率:替格瑞洛+阿司匹林组88.7%(432/487),替格瑞洛单药组82.8%(404/488),阿司匹林单药组76.5%(371/485)。
- 替格瑞洛+阿司匹林与阿司匹林单药比较,通畅率差异12.2%(95%CI 5.2%-19.2%),P<.001。
- 替格瑞洛单药与阿司匹林单药比较,通畅率差异6.3%(95%CI -1.1%-13.7%),P=.10。
- 1年随访期间共发生5例大出血事件:替格瑞洛+阿司匹林组3例,替格瑞洛单药组2例。
临床怎么用
- 对于择期CABG使用大隐静脉桥的患者,术后采用替格瑞洛联合阿司匹林可能改善1年桥血管通畅性。
- 替格瑞洛单药替代阿司匹林单药未显示显著的通畅率优势。
- 需进一步扩大样本量评估替格瑞洛方案的比较性出血风险。
局限性
- 研究为开放标签设计,患者和研究医生均未设盲。
- 样本量500例,需更大样本进一步评估出血风险。
- 研究仅在中国6家三级医院开展,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effect of ticagrelor with or without aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) is unknown. OBJECTIVE: To compare the effect of ticagrelor + aspirin or ticagrelor alone vs aspirin alone on saphenous vein graft patency 1 year after CABG. DESIGN, SETTING, AND PARTICIPANTS: Randomized, multicenter, open-label, clinical trial among 6 tertiary hospitals in China. Eligible patients were aged 18 to 80 years with indications for elective CABG. Patients requiring urgent revascularization, concomitant cardiac surgery, dual antiplatelet or vitamin K antagonist therapy post-CABG, and who were at risk of serious bleeding were excluded. From July 2014 until November 2015, 1256 patients were identified and 500 were enrolled. Follow-up was completed in January 2017. INTERVENTIONS: Patients were randomized (1:1:1) to start ticagrelor (90 mg twice daily) + aspirin (100 mg once daily) (n = 168), ticagrelor (90 mg twice daily) (n = 166), or aspirin (100 mg once daily) (n = 166) within 24 hours post-CABG. Neither patients nor treating physicians were blinded to allocation. MAIN OUTCOMES AND MEASURES: Primary outcome was saphenous vein graft patency 1 year after CABG (FitzGibbon grade A) adjudicated independently by a committee blinded to allocation. Saphenous vein graft patency was assessed by multislice computed tomographic angiography or coronary angiography. RESULTS: Among 500 randomized patients (mean age, 63.6 years; women, 91 [18.2%]), 461 (92.2%) completed the trial. Saphenous vein graft patency rates 1 year post-CABG were 88.7% (432 of 487 vein grafts) with ticagrelor + aspirin; 82.8% (404 of 488 vein grafts) with ticagrelor alone; and 76.5% (371 of 485 vein grafts) with aspirin alone. The difference between ticagrelor + aspirin vs aspirin alone was statistically significant (12.2% [95% CI, 5.2% to 19.2%]; P < .001), whereas the difference between ticagrelor alone vs aspirin alone was not statistically significant (6.3% [95% CI, -1.1% to 13.7%]; P = .10). Five major bleeding episodes occurred during 1 year of follow-up (3 with ticagrelor + aspirin; 2 with ticagrelor alone). CONCLUSIONS AND RELEVANCE: Among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone. Further research with more patients is needed to assess comparative bleeding risks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02201771.
引用
- Zhao Q, Zhu Y, Xu Z, et al. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. 2018. PMID: 29710164. doi:10.1001/jama.2018.3197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。